<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nuvectis Pharma Inc — News on 6ix</title>
<link>https://6ix.com/company/nuvectis-pharma-inc</link>
<description>Latest news and press releases for Nuvectis Pharma Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nuvectis-pharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a42978dffbe2df10a891.webp</url>
<title>Nuvectis Pharma Inc</title>
<link>https://6ix.com/company/nuvectis-pharma-inc</link>
</image>
<item>
<title>Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-upcoming-presentations-for-nxp900-at-the-2026-american-association-for-cancer-research-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-upcoming-presentations-for-nxp900-at-the-2026-american-association-for-cancer-research-meeting</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-inc-reports-2025-123000928</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-inc-reports-2025-123000928</guid>
<pubDate>Wed, 11 Feb 2026 12:30:00 GMT</pubDate>
<description>FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “20</description>
</item>
<item>
<title>Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-initiation-phase-120000475</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-initiation-phase-120000475</guid>
<pubDate>Wed, 17 Dec 2025 12:00:00 GMT</pubDate>
<description>The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose cancers initially responded to treatment with osimertinib but subsequently acquired resistance to treatmentFort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative pre</description>
</item>
<item>
<title>Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-host-virtual-key-130000485</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-host-virtual-key-130000485</guid>
<pubDate>Tue, 25 Nov 2025 13:00:00 GMT</pubDate>
<description>Event scheduled for Tuesday, December 2nd at 8:00 AM ETFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in</description>
</item>
<item>
<title>CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/correction-nuvectis-pharma-inc-reports-131500320</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/correction-nuvectis-pharma-inc-reports-131500320</guid>
<pubDate>Tue, 04 Nov 2025 13:15:00 GMT</pubDate>
<description>FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of th</description>
</item>
<item>
<title>Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-inc-reports-third-123000222</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-inc-reports-third-123000222</guid>
<pubDate>Tue, 04 Nov 2025 12:30:00 GMT</pubDate>
<description>NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosingNXP900 clinical drug-drug interaction study in healthy vol</description>
</item>
<item>
<title>Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-provides-poster-presentation-120000412</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-provides-poster-presentation-120000412</guid>
<pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
<description>Fort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided highlights for NXP900 poster presentations that took place last week at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. Ron Bentsur, Chairman and Chief Executi</description>
</item>
<item>
<title>Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-upcoming-presentations-120000678</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-upcoming-presentations-120000678</guid>
<pubDate>Thu, 16 Oct 2025 12:00:00 GMT</pubDate>
<description>Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA. Titles and PresentersPresentation</description>
</item>
<item>
<title>Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-appoints-biotech-executive-120000763</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-appoints-biotech-executive-120000763</guid>
<pubDate>Thu, 25 Sep 2025 12:00:00 GMT</pubDate>
<description>Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Cor</description>
</item>
<item>
<title>Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-participate-h-c-113000566</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-participate-h-c-113000566</guid>
<pubDate>Thu, 04 Sep 2025 11:30:00 GMT</pubDate>
<description>Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the upcoming H.C. Wainwright Global Investment Conference. A Nuvectis corporate presentation delivered by Ron Bentsur, Chairman and Chief Executi</description>
</item>
<item>
<title>Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-initiation-phase-203000873</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-initiation-phase-203000873</guid>
<pubDate>Mon, 11 Aug 2025 20:30:00 GMT</pubDate>
<description>The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, A</description>
</item>
<item>
<title>Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-inc-reports-second-113000773</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-inc-reports-second-113000773</guid>
<pubDate>Tue, 05 Aug 2025 11:30:00 GMT</pubDate>
<description>NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminentStrengthened cash position following a July At-The-Market (ATM) shares acquisition by a healthcare-dedicated institutional investor; June 30, 2025 proforma cash position of approximately $39 million FORT LEE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis</description>
</item>
<item>
<title>Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-provides-final-clinical-114500847</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-provides-final-clinical-114500847</guid>
<pubDate>Thu, 31 Jul 2025 11:45:00 GMT</pubDate>
<description>Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with intermittent dosing schedule; observed clinical activity warrants exploration of potential development opportunities in other cancer types NXP900 successfully completed a clinical drug-drug interaction (DDI) study in healthy volunteers and the Phase 1a do</description>
</item>
<item>
<title>Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-successful-completion-120000344</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-successful-completion-120000344</guid>
<pubDate>Tue, 08 Jul 2025 12:00:00 GMT</pubDate>
<description>Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.The market leading epidermal growth factor receptor (“EGFR”) and anaplastic lymphoma kinase (“ALK”) inhibitors for the treatment of non-small cell lung cancer (“NSCLC”) are substrates of the Cytochrome P450 (“CYP”) enzyme CYP3A, and therefore their combination with drugs that are strong inducers of</description>
</item>
<item>
<title>Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-present-h-c-203500033</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-present-h-c-203500033</guid>
<pubDate>Fri, 16 May 2025 20:35:00 GMT</pubDate>
<description>Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Inves</description>
</item>
<item>
<title>Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-inc-reports-first-120000083</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-inc-reports-first-120000083</guid>
<pubDate>Tue, 06 May 2025 12:00:00 GMT</pubDate>
<description>NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or th</description>
</item>
<item>
<title>Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-provides-poster-presentation-202500923</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-provides-poster-presentation-202500923</guid>
<pubDate>Tue, 29 Apr 2025 20:25:00 GMT</pubDate>
<description>Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC For</description>
</item>
<item>
<title>Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-upcoming-presentations-120000188</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-upcoming-presentations-120000188</guid>
<pubDate>Wed, 26 Mar 2025 12:00:00 GMT</pubDate>
<description>Fort Lee, NJ, March 26, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2025 American Association for Cancer Research Meeting (2025 AACR), taking place from April 25th to April 30th in Chicago, IL. Presentation</description>
</item>
<item>
<title>Nuvectis Pharma to Participate in the 37th Annual Roth Conference</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-participate-37th-annual-120000149</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-participate-37th-annual-120000149</guid>
<pubDate>Fri, 14 Mar 2025 12:00:00 GMT</pubDate>
<description>FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California. Event37th Annual Roth ConferenceDateMarch</description>
</item>
<item>
<title>Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC</title>
<link>https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-publication-research-130000051</link>
<guid isPermaLink="true">https://6ix.com/company/nuvectis-pharma-inc/news/nuvectis-pharma-announces-publication-research-130000051</guid>
<pubDate>Tue, 04 Mar 2025 13:00:00 GMT</pubDate>
<description>Research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University)Fort Lee, NJ, March 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a new publication from the laboratory of Prof. Ruth Keri, (Cleveland Clinic, Cleve</description>
</item>
</channel>
</rss>